The 7-day direct submission mechanism for technical documentation: Art. 51(3bis) trade-offs and risk control

This article is part of the 50-article series on medical device registration in Switzerland, Volume 2 (Premarket Pathways and Strategy), and is the fourteenth instalment; together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, title and unique URL are shown in the table below.

1. Key takeaways

Art. 51(3bis) provides an optional arrangement, not a default pathway: the manufacturer and the CH-REP may agree that the manufacturer submits technical documentation directly to Swissmedic upon request, yet the responsibility for ensuring submission within 7 days remains with the CH-REP. Choosing direct submission shifts the pressure of response speed from the representative side to the manufacturer side while preserving the statutory backstop on the representative side. The benefit is the manufacturer’s full control over the documentation perimeter and wording; the cost is that archive retrieval and language conversion must be handled in-house, across borders and time zones, within one of the shortest deadlines anywhere in the framework.

2. Legal basis

3. Expert insights

1. The provision changes who holds the documentation, not who is responsible. The EU default is that the authorised representative holds the technical documentation (via Art. 51(3), pointing to Article 11 of the EU MDR); Art. 51(3bis) permits a shift to direct submission by the manufacturer, but the text places the duty to ensure submission within 7 days on the CH-REP. A manufacturer that misreads this as once direct submission is chosen, the representative bears no responsibility creates a liability vacuum that surfaces exactly when a submission runs late.
2. The 7-day period is a hard deadline with no extension mechanism. The period was inserted by the ordinance of 19 May 2021 and entered into force on 26 May 2021 (AS 2021 281); it is shorter than the internal archive retrieval cycles of most companies. The trade-off is explicit: direct submission saves the cost of maintaining a complete duplicate set of technical documentation on Swiss territory, at the price of compressing a cross-border, cross-time-zone, potentially language-conversion-dependent operation into 7 days, every time Swissmedic asks.
3. The trilingual environment magnifies the practical difficulty of direct submission. Art. 16(2) requires product information to be drafted in the three official languages German, French and Italian, and Art. 16(3) sets out four strict conditions for reducing the language set or using English. In a direct submission scenario, the technical documentation submitted by the manufacturer must be aligned with the language versions of the products on sale in Switzerland. If that alignment work is not done in normal times, it is practically impossible to complete it within 7 days (practical estimate).
4. The PRRC is the organisational pivot on which direct submission succeeds or fails. Art. 52(1) requires the CH-REP to maintain a standing PRRC; in the direct submission model, the PRRC judges which documents the request covers and where the submission perimeter lies, while the manufacturer-side executor performs the retrieval. If the two ends have not agreed interfaces and an escalation path in advance, the 7 days will be consumed by internal circulation before anything reaches Swissmedic.

4. Practical recommendations

1. State expressly in the mandate letter whether Art. 51(3bis) is activated; absent a written agreement, the EU default of representative-held documentation applies — never assume direct submission.
2. Agree the starting point of the 7-day period (the date the Swissmedic request reaches the CH-REP or the date it reaches the manufacturer), and name the interfaces on both sides plus a 24-hour escalation path.
3. Build a Switzerland retrieval pack on the manufacturer side: pre-organised to the structure of Annexes II and III of the EU MDR and aligned with the German, French and Italian language versions of the products on sale in Switzerland.
4. Run direct submission and retention in parallel: even when direct submission is chosen, it is advisable for the CH-REP to keep an index and copies of key chapters so the PRRC can complete the scope judgement within 7 days.
5. Fix the retrieval process and time limits in the quality system documentation (with ISO 13485 as one of the baselines) as auditable evidence.

5. Verification checklist

• □ The choice on Art. 51(3bis) (activated or not) has been agreed in writing in the mandate letter.
• □ The starting point of the 7-day period, the interfaces and the escalation path are documented in the operating procedures.
• □ The manufacturer-side Switzerland retrieval pack is ready, with language versions matching the products on sale in Switzerland.
• □ The PRRC of the CH-REP has confirmed familiarity with the direct submission process and can activate it at any time.
• □ The controlled-management records for technical documentation (within the ISO 13485 system) are retrievable on demand.
• □ The potential cost of supplementation requests and correspondence has been assessed at CHF 270 per working hour.

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers entering the Swiss market with registration pathway and classification strategy services, including the Art. 51(3bis) decision, retrieval pack design and 7-day response drills with your CH-REP. For support with Swiss technical documentation readiness, contact GRZAN at info@grzanglobal.com.